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Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is 
associated with an increased risk of colorectal cancer (CRC), possibly due to increased oxidative 
stress and other effects of chronic inflammation. CRC cases arising in association with IBD tend to 
be younger than non-IBD cases, and have other clinical and molecular differences. It has also been 
shown that use of non-steroidal anti-inflammatory medications improves survival after diagnosis with 
CRC, suggesting that inflammation may affect disease progression. 
This led Dr. Scott Adams and colleagues in Public Health Sciences to hypothesize that IBD-
associated CRC cases have worse survival compared to non-IBD-associated CRC cases. Previous 
studies addressing this potential link have mostly been small and hospital-based, and have had 
inconsistent findings. Dr. Adams and colleagues undertook a study using the Colon Cancer Family 
Registry (CCFR) to compare survival and IBD-associated and non-associated CRCs. 
Data on CRC diagnosis, survival, clinical data, and patient characteristics were obtained using the 
CCFR. Investigators identified IBD-associated cases as those CRC patients who had previously 
been diagnosed with either ulcerative colitis or Crohn’s disease, according to their initial interview at 
CCFR enrollment. The investigators checked the accuracy of these data by reviewing medical 
records for IBD diagnosis in a subset of participants. 
7,202 CRC cases were included in the study, of which 250 were IBD-associated cases. 2,013 
deaths occurred in non-IBD-associated cases (29%), and 74 in IBD-associated cases (30%), 12 
years after diagnosis with CRC. After accounting for differences in age at CRC diagnosis, sex, 
number of prior endoscopies, and CCFR phase, there was evidence of poorer 5-year survival for 
IBD-associated CRC compared to non-IBD-associated CRC. Specifically, IBD-associated cases 
were 36% more likely to die within 5 years of diagnosis than non-IBD-associated cases (hazard ratio 
(HR) 1.36, 95% confidence interval (CI) 1.05-1.76). Even after accounting for differences in CRC 
stage at diagnosis, survival was still worse in IBD-associated cases, suggesting that IBD-associated 
CRC progresses more quickly than non-IBD-associated CRC. 
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The investigators conducted additional analyses restricted to IBD diagnoses confirmed by medical 
record review, and stratified by duration of IBD before CRC diagnosis. Results were similar in these 
analyses. When looking separately at ulcerative colitis versus Crohn’s disease, there was some 
evidence that patients with only Crohn’s disease were less likely to survive to 5 years (HR: 1.74, 
95% CI 1.09-2.79) than patients with only ulcerative colitis (HR 1.18, 95% CI 0.85-1.63). 
Based on this study, IBD-associated CRC appears to have poorer 5-year survival than non-IBD-
associated CRC. Because of limitations in the data, the investigators were unable to assess the 
effects of differences in treatment of CRC or IBD, or identify which IBD patients had received 
surveillance for CRC. They also were unable to reliably compare longer-term survival. 
“I think the question [this study] raises is why there is a difference in survival between CRC patients 
where cancer develops within IBD, and “sporadic” CRC,” Dr. Adams noted. He points out that 
perhaps IBD patients just have poorer health in general due to the seriousness of IBD, or 
alternatively, “Do these comorbidities [of IBD] make it difficult to complete cancer treatment? Or is 
there something different biologically about the tumors?” 
This research group plans to follow up on this work by looking at genetic differences in the IBD-
associated and non-IBD associated cancers. “We are planning to go back to the Colon CFR tumor 
archives and see how the mutation spectrum differs between these two types of tumors…, for 
important gene mutations associated with CRC.” Dr. Adams notes that most previous studies of this 
question have been based on much smaller studies, and that the relatively large size of the CCFR 
will be useful. 
 
Adams SV, Ahnen DJ, Baron JA, Campbell PT, Gallinger S, Grady WM, Lemarchand L, Lindor NM, 
Potter JD, Newcomb PA. 2013. Survival after inflammatory bowel disease-associated colorectal 
cancer in the Colon Cancer Family Registry. World Journal of Gastroenterology 19(21):3241-3248. 
doi: 10.3748/wjg.v19.i21.3241. 
 
 
 
 
July 15, 2013 SCIENCE SPOTLIGHT 
 
3 Volume 3, Issue 7 | Fred Hutchinson Cancer Research Center 
 
 
 
Image provided by the author 
Survival probability for non-IBD-associated (solid line) 
and IBD-associated colorectal cancer (dashed line), after 
adjusting for confounders. 
 
